Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 14/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.81 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.60 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938473 | 0.99 | L3MBTL3 (0.83) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL4938412 | 0.93 | L3MBTL3 (0.73) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL3528306 | 0.91 | L3MBTL3 (0.97) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| Hydrochloric Acid SCHEMBL3528657 | 0.90 | L3MBTL3 (0.94) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL23682967 | 0.90 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4935130 | 0.86 | L3MBTL3 (0.64) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL23682720 | 0.85 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL4937224 | 0.82 | HRH3 (0.62) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL5077433 | 0.82 | HRH3 (0.72) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL4292175 | 0.82 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | L3MBTL3 4833/4885L3MBTL1 4814/4885MBTD1 3982/4885 |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | HRH2, HNMT, HRH3 | L3MBTL3 4833/4885L3MBTL1 4814/4885MBTD1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.